Search For a Provider Facebook Twitter Instagram YouTube ES View the Patient Toolkit


Study: ED Drugs Don’t Increase Risk for Prostate Cancer Recurrence

Feb 03, 2016

Study: ED Drugs Don’t Increase Risk for Prostate Cancer RecurrenceNew research suggests that oral drugs for erectile dysfunction (ED) don’t increase a man’s risk for biochemical recurrence of prostate cancer.

The term “biochemical recurrence” refers to the possibility that prostate cancer has come back after treatment. This occurs when a PSA (prostate-specific antigen) test shows that PSA levels have increased. Elevated PSA levels are not always a sign of cancer, but they can warrant further testing.


Study: ED drugs don’t increase risk for prostate cancer recurrence. (Click to tweet)


Past research has raised concerns that ED medications called phosphodiesterase type 5 (PDE5) inhibitors - Viagra, Levitra, and Cialis - increase the risk of recurrence. These drugs are usually the first-line therapy for ED.

To learn more, scientists from Europe and the United States examined medical data from the National Prostate Cancer Register of Sweden linked to the Prescribed Drug Register. They identified men who had been treated for localized prostate cancer (confined to the prostate gland) and looked at 5 years of follow-up data.


1 2 Next » (page 1 of 2)